Explore the words cloud of the C9ND project. It provides you a very rough idea of what is the project "C9ND" about.
The following table provides information about the project.
Coordinator |
UNIVERSITY COLLEGE LONDON
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Project website | http://adrianisaacslab.com/ |
Total cost | 1˙985˙699 € |
EC max contribution | 1˙985˙699 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2014-CoG |
Funding Scheme | ERC-COG |
Starting year | 2015 |
Duration (year-month-day) | from 2015-10-01 to 2020-09-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | UNIVERSITY COLLEGE LONDON | UK (LONDON) | coordinator | 1˙985˙699.00 |
An expanded GGGGCC repeat in a non-coding region of the C9orf72 gene is the most common known cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The repeat RNA is transcribed and accumulates in neuronal RNA aggregates, implicating RNA toxicity as a key pathogenic mechanism. However, the pathways that lead to neurodegeneration are unknown. My lab has made pioneering contributions to the understanding of C9orf72 FTD/ALS, and reported the first structure of the repeat RNA, and the first description of both sense and antisense RNA aggregates in patient brain. We have now developed new disease models that allow, for the first time, the dissection of RNA toxicity both in vivo and in sophisticated neuronal culture models. We have also used our knowledge of the repeat structure to identify novel small molecules that show very strong binding to the repeats. We will utilise our innovative disease models in a multidisciplinary approach to fully dissect the cellular pathways underlying C9orf72 repeat RNA toxicity in vivo, on a genome-wide scale. Altered RNA metabolism has been implicated in a wide range of neurodegenerative diseases, indicating that our findings will provide profound new insight into fundamental mechanisms of neuronal maintenance and survival. This research programme will also deliver a step change in our understanding of C9orf72 FTD/ALS pathogenesis and provide essential insight for the identification of small molecules with genuine therapeutic potential. RNA-mediated mechanisms are now known to be a common theme in neurodegeneration, suggesting these findings will have broad significance.
year | authors and title | journal | last update |
---|---|---|---|
2017 |
Sarah Mizielinska, Charlotte E. Ridler, Rubika Balendra, Annora Thoeng, Nathan S. Woodling, Friedrich A. Grässer, Vincent Plagnol, Tammaryn Lashley, Linda Partridge, Adrian M. Isaacs Bidirectional nucleolar dysfunction in C9orf72 frontotemporal lobar degeneration published pages: , ISSN: 2051-5960, DOI: 10.1186/s40478-017-0432-x |
Acta Neuropathologica Communications 5/1 | 2019-06-06 |
2018 |
Roberto Simone, Rubika Balendra, Thomas G Moens, Elisavet Preza, Katherine M Wilson, Amanda Heslegrave, Nathan S Woodling, Teresa Niccoli, Javier Gilbertâ€Jaramillo, Samir Abdelkarim, Emma L Clayton, Mica Clarke, Marieâ€Therese Konrad, Andrew J Nicoll, Jamie S Mitchell, Andrea Calvo, Adriano Chio, Henry Houlden, James M Polke, Mohamed A Ismail, Chad E Stephens, Tam Vo, Abdelbasset A Farahat, W David Wilson, David W Boykin, Henrik Zetterberg, Linda Partridge, Selina Wray, Gary Parkinson, Stephen Neidle, Rickie Patani, Pietro Fratta, Adrian M Isaacs Gâ€quadruplexâ€binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo published pages: 22-31, ISSN: 1757-4676, DOI: 10.15252/emmm.201707850 |
EMBO Molecular Medicine 10/1 | 2019-06-06 |
2017 |
Teresa Niccoli, Linda Partridge, Adrian M. Isaacs Ageing as a risk factor for ALS/FTD published pages: R105-R113, ISSN: 0964-6906, DOI: 10.1093/hmg/ddx247 |
Human Molecular Genetics 26/R2 | 2019-06-06 |
2016 |
S. Mizielinska, A. M. Isaacs One target for amyotrophic lateral sclerosis therapy? published pages: 647-648, ISSN: 0036-8075, DOI: 10.1126/science.aah5408 |
Science 353/6300 | 2019-06-06 |
2017 |
Rubika Balendra, Thomas G Moens, Adrian M Isaacs Specific biomarkers for C9orf72 FTD/ALS could expedite the journey towards effective therapies published pages: 853-855, ISSN: 1757-4676, DOI: 10.15252/emmm.201707848 |
EMBO Molecular Medicine 9/7 | 2019-06-06 |
2018 |
Thomas G. Moens, Sarah Mizielinska, Teresa Niccoli, Jamie S. Mitchell, Annora Thoeng, Charlotte E. Ridler, Sebastian Grönke, Jacqueline Esser, Amanda Heslegrave, Henrik Zetterberg, Linda Partridge, Adrian M. Isaacs Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD published pages: 445-457, ISSN: 0001-6322, DOI: 10.1007/s00401-017-1798-3 |
Acta Neuropathologica 135/3 | 2019-06-06 |
2017 |
Guillaume M. Hautbergue, Lydia M. Castelli, Laura Ferraiuolo, Alvaro Sanchez-Martinez, Johnathan Cooper-Knock, Adrian Higginbottom, Ya-Hui Lin, Claudia S. Bauer, Jennifer E. Dodd, Monika A. Myszczynska, Sarah M. Alam, Pierre Garneret, Jayanth S. Chandran, Evangelia Karyka, Matthew J. Stopford, Emma F. Smith, Janine Kirby, Kathrin Meyer, Brian K. Kaspar, Adrian M. Isaacs, Sherif F. El-Khamisy, Kurt J. De Vos, Ke Ning, Mimoun Azzouz, Alexander J. Whitworth, Pamela J. Shaw SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits published pages: 16063, ISSN: 2041-1723, DOI: 10.1038/ncomms16063 |
Nature Communications 8 | 2019-06-06 |
2018 |
Bart Swinnen, Andre Bento-Abreu, Tania F. Gendron, Steven Boeynaems, Elke Bogaert, Rik Nuyts, Mieke Timmers, Wendy Scheveneels, Nicole Hersmus, Jiou Wang, Sarah Mizielinska, Adrian M. Isaacs, Leonard Petrucelli, Robin Lemmens, Philip Van Damme, Ludo Van Den Bosch, Wim Robberecht A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism published pages: 427-443, ISSN: 0001-6322, DOI: 10.1007/s00401-017-1796-5 |
Acta Neuropathologica 135/3 | 2019-06-06 |
2017 |
Thomas G Moens, Linda Partridge, Adrian M Isaacs Genetic models of C9orf72 : what is toxic? published pages: 92-101, ISSN: 0959-437X, DOI: 10.1016/j.gde.2017.01.006 |
Current Opinion in Genetics & Development 44 | 2019-06-06 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "C9ND" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "C9ND" are provided by the European Opendata Portal: CORDIS opendata.
Cancer heterogeneity and therapy profiling using bioresponsive nanohydrogels for the delivery of multicolor logic genetic circuits.
Read MoreDiscovering a novel allergen immunotherapy in house dust mite allergy tolerance research
Read MoreConstraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks
Read More